



Clinical trial results:

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction

Summary

EudraCT number	2016-002299-28
Trial protocol	FR DE BE SE CZ ES HU NL GB PT PL AT SK BG LT GR IT
Global end of trial date	14 September 2020

Results information

Result version number	v1 (current)
This version publication date	28 June 2021
First version publication date	28 June 2021

Trial information

Trial identification

Sponsor protocol code	20110203
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02929329
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Amgen Inc.
Sponsor organisation address	One Amgen Center Drive, Thousand Oaks, CA, United States, 91320
Public contact	IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com
Scientific contact	IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	14 September 2020
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	14 September 2020
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The purpose of this study was to determine if treatment with omecamtiv mecarbil (OM) when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in adults with chronic heart failure with reduced ejection fraction (HFrEF).

Protection of trial subjects:

This study was conducted in accordance with International Council for Harmonisation (ICH) Good Clinical Practice (GCP) and applicable national or regional regulations/guidelines.

The Independent Ethics Committee (IEC) and Institutional Review Board (IRB) for this study reviewed the study protocol and amendments and the informed consent form (ICF).

The investigator or his/her designee informed the subject of all aspects pertaining to the subject's participation in the study before any screening procedures were performed.

Background therapy:

Participants were required to be optimally managed with standard of care therapies for chronic HF (eg, beta blockers, renin angiotensin aldosterone system inhibitors), consistent with regional clinical practice guidelines, unless contraindicated.

Evidence for comparator: -

Actual start date of recruitment	06 January 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	China: 400
Country: Number of subjects enrolled	Japan: 270
Country: Number of subjects enrolled	Bulgaria: 195
Country: Number of subjects enrolled	Hungary: 394
Country: Number of subjects enrolled	Lithuania: 83
Country: Number of subjects enrolled	Poland: 573
Country: Number of subjects enrolled	Romania: 149
Country: Number of subjects enrolled	Russian Federation: 419
Country: Number of subjects enrolled	Slovakia: 89
Country: Number of subjects enrolled	Turkey: 281
Country: Number of subjects enrolled	Ukraine: 275
Country: Number of subjects enrolled	Argentina: 466
Country: Number of subjects enrolled	Brazil: 480
Country: Number of subjects enrolled	Chile: 138
Country: Number of subjects enrolled	Colombia: 252

Country: Number of subjects enrolled	Mexico: 238
Country: Number of subjects enrolled	Canada: 166
Country: Number of subjects enrolled	United States: 1220
Country: Number of subjects enrolled	Australia: 116
Country: Number of subjects enrolled	Austria: 62
Country: Number of subjects enrolled	Belgium: 40
Country: Number of subjects enrolled	Denmark: 47
Country: Number of subjects enrolled	France: 206
Country: Number of subjects enrolled	Germany: 207
Country: Number of subjects enrolled	Greece: 203
Country: Number of subjects enrolled	Italy: 163
Country: Number of subjects enrolled	Netherlands: 138
Country: Number of subjects enrolled	New Zealand: 43
Country: Number of subjects enrolled	Portugal: 79
Country: Number of subjects enrolled	South Africa: 175
Country: Number of subjects enrolled	Spain: 175
Country: Number of subjects enrolled	Sweden: 52
Country: Number of subjects enrolled	Switzerland: 39
Country: Number of subjects enrolled	United Kingdom: 176
Country: Number of subjects enrolled	Czechia: 223
Worldwide total number of subjects	8232
EEA total number of subjects	3078

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	3747
From 65 to 84 years	4431
85 years and over	54

Subject disposition

Recruitment

Recruitment details:

A total of 11,121 patients underwent screening at 944 sites in 35 countries. Of these patients, 8,256 were randomized, but 24 patients from one site were excluded because of Good Clinical Practice violations and are not included in the data reported below.

Pre-assignment

Screening details:

Participants were randomly assigned in a 1:1 ratio to receive either OM or placebo.

Randomization was stratified by randomization setting (currently hospitalized for HF or recently and not currently hospitalized for HF) and region (US and Canada; Latin America; Western Europe, South Africa, and Australasia; Eastern Europe including Russia; Asia).

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Data analyst, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Participants received matching placebo tablets twice a day (BID).

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Matching placebo tablets taken twice a day

Arm title	Omecamtiv Mecarbil
------------------	--------------------

Arm description:

Participants received oral omecamtiv mecarbil BID. The starting dose was 25 mg; the dose may have been adjusted at week 4 to 37.5 or 50 mg based on the predose plasma concentration measured at week 2.

Arm type	Experimental
Investigational medicinal product name	Omecamtiv Mecarbil
Investigational medicinal product code	AMG 423
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Administered orally twice a day

Number of subjects in period 1	Placebo	Omecamtiv Mecarbil
Started	4112	4120
Received Treatment	4101	4110
Completed	3008	3028
Not completed	1104	1092
Adverse event, serious fatal	1054	1051
Consent withdrawn by subject	24	21
Lost to follow-up	26	20

Baseline characteristics

Reporting groups

Reporting group title	Placebo
Reporting group description:	
Participants received matching placebo tablets twice a day (BID).	
Reporting group title	Omecamtiv Mecarbil
Reporting group description:	
Participants received oral omecamtiv mecarbil BID. The starting dose was 25 mg; the dose may have been adjusted at week 4 to 37.5 or 50 mg based on the predose plasma concentration measured at week 2.	

Reporting group values	Placebo	Omecamtiv Mecarbil	Total
Number of subjects	4112	4120	8232
Age Categorical			
Units: participants			
18 to 64 years	1873	1874	3747
65 to 84 years	2211	2220	4431
85 years and over	28	26	54
Age Continuous			
Units: years			
arithmetic mean	64.5	64.5	-
standard deviation	± 11.4	± 11.3	-
Sex: Female, Male			
Units: participants			
Female	874	875	1749
Male	3238	3245	6483
Race/Ethnicity, Customized			
Units: Subjects			
American Indian or Alaska Native	38	35	73
Asian	355	355	710
Black or African American	277	285	562
Multiple	96	99	195
Native Hawaiian or Other Pacific Islander	6	7	13
White	3201	3196	6397
Other	139	143	282
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	885	886	1771
Not Hispanic or Latino	3227	3234	6461
Unknown or Not Reported	0	0	0
Randomization Setting			
Units: Subjects			
Currently hospitalized for heart failure	1050	1051	2101
Recently and not currently hospitalized for HF	3062	3069	6131
Region			
Units: Subjects			

United States and Canada	693	693	1386
Latin America	787	787	1574
Western Europe, South Africa, and Australasia	960	961	1921
Eastern Europe including Russia	1337	1344	2681
Asia	335	335	670

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description: Participants received matching placebo tablets twice a day (BID).	
Reporting group title	Omecamtiv Mecarbil
Reporting group description: Participants received oral omecamtiv mecarbil BID. The starting dose was 25 mg; the dose may have been adjusted at week 4 to 37.5 or 50 mg based on the predose plasma concentration measured at week 2.	
Subject analysis set title	Placebo: Outpatients
Subject analysis set type	Full analysis
Subject analysis set description: Participants who had either made an urgent visit to the emergency department or been hospitalized for heart failure within 1 year before screening received placebo tablets twice a day.	
Subject analysis set title	Omecamtiv Mecarbil: Outpatients
Subject analysis set type	Full analysis
Subject analysis set description: Participants who had either made an urgent visit to the emergency department or been hospitalized for heart failure within 1 year before screening received oral omecamtiv mecarbil twice daily. The starting dose was 25 mg; the dose could be adjusted at week 4 to 37.5 or 50 mg based on the predose plasma concentration measured at week 2.	
Subject analysis set title	Placebo: Inpatients
Subject analysis set type	Full analysis
Subject analysis set description: Participants who were currently hospitalized for heart failure received placebo tablets twice a day.	
Subject analysis set title	Omecamtiv Mecarbil: Inpatients
Subject analysis set type	Full analysis
Subject analysis set description: Participants who were currently hospitalized for heart failure received oral omecamtiv mecarbil twice daily. The starting dose was 25 mg; the dose could be adjusted at week 4 to 37.5 or 50 mg based on the predose plasma concentration measured at week 2.	

Primary: Time to Cardiovascular Death or First Heart Failure Event

End point title	Time to Cardiovascular Death or First Heart Failure Event
End point description: The primary outcome was a composite of a heart-failure (HF) event or cardiovascular death, whichever occurred first, in a time-to-event analysis. A heart-failure event was defined as an urgent clinic visit, emergency department visit, or hospitalization for subjectively and objectively worsening heart failure leading to treatment intensification beyond a change in oral diuretic therapy. All deaths and HF events were adjudicated by an independent external clinical events committee (CEC) at the Duke Clinical Research Institute, using standardized definitions based on the recent American College of Cardiology/American Heart Association (ACC/AHA) standards for endpoint definitions in cardiovascular clinical trials. The percentage of participants with a positively adjudicated event during the study is reported.	
End point type	Primary
End point timeframe: From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months (interquartile range, 15.4 to 28.6).	

End point values	Placebo	Omecamtiv Mecarbil		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4112	4120		
Units: percentage of participants				
number (not applicable)	39.1	37.0		

Statistical analyses

Statistical analysis title	Primary Analysis
Comparison groups	Placebo v Omecamtiv Mecarbil
Number of subjects included in analysis	8232
Analysis specification	Pre-specified
Analysis type	superiority ^[1]
P-value	= 0.0252
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.92
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.86
upper limit	0.99

Notes:

[1] - The overall type I error was 0.05 for 2-sided testing across primary and secondary outcomes. Control for multiple comparisons was achieved using the following testing algorithm: if the primary outcome met the P-value threshold of 0.05, the alpha error would be divided unequally between cardiovascular death (96% of the overall alpha error, or 0.048) and change from baseline to week 24 in the Kansas City Cardiomyopathy Questionnaire total symptom score (4% of the overall alpha error, or 0.002).

Statistical analysis title	Additional Analysis: Stratified Log-rank Test
Comparison groups	Placebo v Omecamtiv Mecarbil
Number of subjects included in analysis	8232
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0211
Method	Stratified log-rank test

Statistical analysis title	Sensitivity Analysis: Competing Risk Analysis
Statistical analysis description:	
Competing risk subdistribution hazard ratio and associated 95% confidence intervals for treatment were computed. Deaths not included in the endpoint were considered as the competing risk.	
Comparison groups	Placebo v Omecamtiv Mecarbil

Number of subjects included in analysis	8232
Analysis specification	Post-hoc
Analysis type	superiority
Parameter estimate	Hazard ratio (HR)
Point estimate	0.92
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.86
upper limit	0.99

Secondary: Time to Cardiovascular Death

End point title	Time to Cardiovascular Death
End point description:	
Cardiovascular death includes acute myocardial infarction (MI), sudden cardiac death, death due to heart failure, death due to stroke, death due to cardiovascular (CV) procedures, death due to CV hemorrhage, and death due to other CV causes.	
All deaths were adjudicated by an independent external clinical-events committee at the Duke Clinical Research Institute, using standardized definitions based on the recent ACC/AHA standards for endpoint definitions in cardiovascular clinical trials.	
The percentage of participants with a positively adjudicated event during the study is reported.	
End point type	Secondary
End point timeframe:	
From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months (interquartile range, 15.4 to 28.6).	

End point values	Placebo	Omecamtiv Mecarbil		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4112	4120		
Units: percentage of participants				
number (not applicable)	19.4	19.6		

Statistical analyses

Statistical analysis title	Primary Analysis
Comparison groups	Placebo v Omecamtiv Mecarbil
Number of subjects included in analysis	8232
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8555 ^[2]
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.01

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.92
upper limit	1.11

Notes:

[2] - If significance for the primary outcome was determined, cardiovascular death was tested against an alpha of 0.048.

Statistical analysis title	Sensitivity Analysis: Competing Risk Analysis
-----------------------------------	---

Statistical analysis description:

Competing risk subdistribution hazard ratio and associated 95% confidence intervals for treatment were computed. Deaths not included in the endpoint were considered as the competing risk.

Comparison groups	Placebo v Omecamtiv Mecarbil
Number of subjects included in analysis	8232
Analysis specification	Post-hoc
Analysis type	superiority
Parameter estimate	Hazard ratio (HR)
Point estimate	1.01

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.92
upper limit	1.11

Secondary: Change From Baseline in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ TSS) at Week 24

End point title	Change From Baseline in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ TSS) at Week 24
-----------------	--

End point description:

The Kansas City Cardiomyopathy Questionnaire is a self-administered questionnaire with a 2-week recall period that includes 23 items that map to 7 domains: symptom frequency; symptom burden; symptom stability; physical limitations; social limitations; quality of life; and self-efficacy (the patient's understanding of how to manage their heart failure). The symptom frequency and symptom burden domains are merged into a total symptom score. Scores are represented on a 0-to-100-point scale, where lower scores represent more frequent and severe symptoms and scores of 100 indicate no symptoms.

The change from baseline in KCCQ TSS was analyzed separately for each randomization setting (inpatient and outpatient).

Least squares means are from the mixed model which includes baseline total symptom score value, region, baseline eGFR, scheduled visit, treatment group and interaction of treatment with scheduled visit as covariates.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 24

End point values	Placebo: Outpatients	Omecamtiv Mecarbil: Outpatients	Placebo: Inpatients	Omecamtiv Mecarbil: Inpatients
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	2704	2715	835	868
Units: scores on a scale				
least squares mean (standard error)	6.29 (\pm 0.34)	5.83 (\pm 0.34)	21.15 (\pm 0.71)	23.65 (\pm 0.70)

Statistical analyses

Statistical analysis title	Outpatients Treatment Difference
Comparison groups	Placebo: Outpatients v Omecamtiv Mecarbil: Outpatients
Number of subjects included in analysis	5419
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Least Squares (LS) Mean Difference
Point estimate	-0.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	0.48
Variability estimate	Standard error of the mean
Dispersion value	0.48

Statistical analysis title	Inpatients Treatment Difference
Comparison groups	Placebo: Inpatients v Omecamtiv Mecarbil: Inpatients
Number of subjects included in analysis	1703
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	LS Mean Difference
Point estimate	2.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.54
upper limit	4.46
Variability estimate	Standard error of the mean
Dispersion value	1

Statistical analysis title	Primary Analysis
Comparison groups	Placebo: Outpatients v Omecamtiv Mecarbil: Outpatients v Placebo: Inpatients v Omecamtiv Mecarbil: Inpatients

Number of subjects included in analysis	7122
Analysis specification	Pre-specified
Analysis type	superiority ^[3]
P-value	= 0.0278
Method	Omnibus F-test

Notes:

[3] - If significance for the primary outcome was determined, change from baseline in the KCCQ total symptom score was tested against an alpha of 0.002.

Statistical analysis title	Overall Pooled Treatment Difference
Comparison groups	Placebo: Outpatients v Omecamtiv Mecarbil: Outpatients v Placebo: Inpatients v Omecamtiv Mecarbil: Inpatients
Number of subjects included in analysis	7122
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Pooled treatment difference
Point estimate	0.75
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.55
upper limit	4.51

Statistical analysis title	Sensitivity Analysis: Joint Model
-----------------------------------	-----------------------------------

Statistical analysis description:

As a sensitivity for missing data due to death, joint longitudinal and survival models were fit using KCCQ TSS observed values with random subject slopes and intercepts for the longitudinal models with terms for baseline eGFR, region, and treatment by slope. The survival models were fit for all-cause death with baseline eGFR and treatment in the proportional hazard part of the models, KCCQ TSS modeled values as the shared parameterization, stratified by region with Weibull baseline functions.

Comparison groups	Placebo: Outpatients v Omecamtiv Mecarbil: Outpatients
Number of subjects included in analysis	5419
Analysis specification	Post-hoc
Analysis type	superiority
Parameter estimate	LS Mean Difference
Point estimate	-0.71
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.62
upper limit	0.2

Statistical analysis title	Sensitivity Analysis: Joint Model
-----------------------------------	-----------------------------------

Statistical analysis description:

As a sensitivity for missing data due to death, joint longitudinal and survival models were fit using KCCQ TSS observed values with random subject slopes and intercepts for the longitudinal models with terms for baseline eGFR, region, and treatment by slope. The survival models were fit for all-cause death with baseline eGFR and treatment in the proportional hazard part of the models, KCCQ TSS modeled values as the shared parameterization, stratified by region with Weibull baseline functions.

Comparison groups	Placebo: Inpatients v Omecamtiv Mecarbil: Inpatients
Number of subjects included in analysis	1703
Analysis specification	Post-hoc
Analysis type	superiority
Parameter estimate	LS mean difference
Point estimate	2.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.8
upper limit	3.82

Secondary: Time to First Heart Failure Hospitalization

End point title	Time to First Heart Failure Hospitalization
-----------------	---

End point description:

A HF hospitalization is defined as an event that met all of the following criteria:

- 1) The participant was admitted to the hospital with a primary diagnosis of HF;
- 2) The participant's length of stay in the hospital extended for at least 24 hours;
- 3) The participant exhibited documented new or worsening symptoms due to HF on presentation;
- 4) The participant had objective evidence of new or worsening HF;
- 5) The participant received initiation or intensification of treatment specifically for HF, including an intravenous diuretic or vasoactive agent, mechanical or surgical intervention, or mechanical fluid removal.

All events were adjudicated by an independent external CEC at the Duke Clinical Research Institute, using standardized definitions based on the recent ACC/AHA standards for endpoint definitions in cardiovascular clinical trials.

The percentage of participants with a positively adjudicated event during the study is reported.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months (interquartile range, 15.4 to 28.6).

End point values	Placebo	Omecamtiv Mecarbil		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4112	4120		
Units: percentage of participants				
number (not applicable)	28.7	27.7		

Statistical analyses

Statistical analysis title	Primary Analysis
Comparison groups	Placebo v Omecamtiv Mecarbil

Number of subjects included in analysis	8232
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1902 ^[4]
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.87
upper limit	1.03

Notes:

[4] - If statistical significance was achieved for both the time to CV death and change from baseline in the KCCQ TSS, time to first heart failure hospitalization was to be tested at the full alpha.

Statistical analysis title	Sensitivity Analysis: Competing Risk Analysis
-----------------------------------	---

Statistical analysis description:

Competing risk subdistribution hazard ratio and associated 95% confidence intervals for treatment were computed. Deaths not included in the endpoint are considered as the competing risk.

Comparison groups	Placebo v Omecamtiv Mecarbil
Number of subjects included in analysis	8232
Analysis specification	Post-hoc
Analysis type	superiority
Parameter estimate	Hazard ratio (HR)
Point estimate	0.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.88
upper limit	1.04

Secondary: Time to All-cause Death

End point title	Time to All-cause Death
-----------------	-------------------------

End point description:

All events were adjudicated by an independent external clinical-events committee at the Duke Clinical Research Institute, using standardized definitions based on the recent ACC/AHA standards for endpoint definitions in cardiovascular clinical trials.

The percentage of participants with an event are reported.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months (interquartile range, 15.4 to 28.6).

End point values	Placebo	Omecamtiv Mecarbil		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4112	4120		
Units: percentage of participants				
number (not applicable)	25.9	25.9		

Statistical analyses

Statistical analysis title	Primary Analysis
Comparison groups	Placebo v Omecamtiv Mecarbil
Number of subjects included in analysis	8232
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9633 ^[5]
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.92
upper limit	1.09

Notes:

[5] - If time to first heart failure hospitalization was statistically significant, time to all-cause death was to be tested with the same alpha as time to first heart failure hospitalization.

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Deaths are reported from 1st dose of drug until end of study; median (min, max) time on study was 21.8 (0, 42) months. AEs are reported from 1st dose of drug until 30 days after last dose; median (min, max) treatment duration was 19.5 (0, 42) months.

Adverse event reporting additional description:

The safety population included all participants who received at least 1 dose of study drug.

In addition to the deaths reported below, seven subjects who were randomized but who did not receive any study drug also died during the study.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.0
--------------------	------

Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Participants received matching placebo tablets twice a day.

Reporting group title	Omecamtiv Mecarbil
-----------------------	--------------------

Reporting group description:

Participants received oral omecamtiv mecarbil BID. The starting dose was 25 mg; the dose may have been adjusted at week 4 to 37.5 or 50 mg based on the predose plasma concentration measured at week 2.

Serious adverse events	Placebo	Omecamtiv Mecarbil	
Total subjects affected by serious adverse events			
subjects affected / exposed	2435 / 4101 (59.38%)	2373 / 4110 (57.74%)	
number of deaths (all causes)	1075	1074	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Adenocarcinoma gastric			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Adenocarcinoma of colon			

subjects affected / exposed	7 / 4101 (0.17%)	5 / 4110 (0.12%)	
occurrences causally related to treatment / all	0 / 8	0 / 7	
deaths causally related to treatment / all	0 / 1	0 / 0	
Adenocarcinoma pancreas			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenosquamous cell lung cancer stage III			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Adrenal adenoma			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
B-cell lymphoma			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Basal cell carcinoma			
subjects affected / exposed	1 / 4101 (0.02%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basosquamous carcinoma			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of testis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder adenocarcinoma stage 0			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neoplasm			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone sarcoma			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangiocarcinoma			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Colon adenoma			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic lymphocytic leukaemia			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer			

subjects affected / exposed	7 / 4101 (0.17%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 7	0 / 7	
deaths causally related to treatment / all	0 / 1	0 / 1	
Colon cancer metastatic			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Colorectal cancer			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal cancer metastatic			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Diffuse large B-cell lymphoma			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Endometrial adenocarcinoma			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Essential thrombocythaemia			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric cancer			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Gallbladder cancer metastatic			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Gastrointestinal stromal tumour			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glioblastoma			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glioblastoma multiforme			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cancer			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hepatic cancer metastatic			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypopharyngeal cancer			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Invasive ductal breast carcinoma			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Keratoacanthoma			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal squamous cell carcinoma			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lipoma			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liposarcoma			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma			
subjects affected / exposed	1 / 4101 (0.02%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma stage II			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Lung cancer metastatic			
subjects affected / exposed	2 / 4101 (0.05%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 1	
Lung carcinoma cell type unspecified stage III			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung carcinoma cell type unspecified stage IV			

subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm			
subjects affected / exposed	3 / 4101 (0.07%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Lung neoplasm malignant			
subjects affected / exposed	5 / 4101 (0.12%)	6 / 4110 (0.15%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 2	0 / 5	
Lymphangiosis carcinomatosa			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Lymphoma			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant neoplasm progression			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mediastinum neoplasm			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medullary thyroid cancer			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melanoma recurrent			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to bone			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Metastases to liver			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to lymph nodes			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to peritoneum			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastasis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic bronchial carcinoma			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metastatic neoplasm			

subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Myelodysplastic syndrome			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelofibrosis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasopharyngeal cancer			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Neoplasm malignant			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 0	
Neoplasm skin			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine carcinoma			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine carcinoma of the skin			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine tumour of the lung metastatic			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-Hodgkin's lymphoma			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-small cell lung cancer			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Non-small cell lung cancer stage IV			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal adenocarcinoma			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal carcinoma			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Oesophageal neoplasm			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Oesophageal squamous cell carcinoma			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal squamous cell carcinoma stage IV			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cancer			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pancreatic carcinoma			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pancreatic carcinoma metastatic			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 1	
Pancreatic neoplasm			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Papillary thyroid cancer			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Penile cancer			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Penile squamous cell carcinoma			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plasma cell myeloma			

subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Prostate cancer			
subjects affected / exposed	6 / 4101 (0.15%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer metastatic			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Prostate cancer recurrent			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer stage I			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer stage IV			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic adenoma			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal adenocarcinoma			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal cancer			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal cancer metastatic			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Rectal neoplasm			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cancer			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cell carcinoma			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal neoplasm			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small cell lung cancer metastatic			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small cell lung cancer			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Squamous cell carcinoma			

subjects affected / exposed	2 / 4101 (0.05%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Squamous cell carcinoma of lung			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Squamous cell carcinoma of pharynx			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the cervix			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the tongue			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid adenoma			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsil cancer			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transitional cell carcinoma			
subjects affected / exposed	3 / 4101 (0.07%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Ureteric cancer			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine leiomyoma			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Aortic aneurysm			
subjects affected / exposed	5 / 4101 (0.12%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic aneurysm rupture			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Aortic dissection			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic dissection rupture			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Aortic rupture			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Aortic stenosis			
subjects affected / exposed	4 / 4101 (0.10%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Arterial disorder			

subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial haemorrhage			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial occlusive disease			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial perforation			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial stenosis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerosis			
subjects affected / exposed	2 / 4101 (0.05%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 2	
Axillary vein thrombosis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brachiocephalic vein thrombosis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			

subjects affected / exposed	7 / 4101 (0.17%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 7	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic macroangiopathy			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Distributive shock			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Dry gangrene			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolism arterial			
subjects affected / exposed	0 / 4101 (0.00%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extremity necrosis			
subjects affected / exposed	3 / 4101 (0.07%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma			
subjects affected / exposed	4 / 4101 (0.10%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemodynamic instability			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			

subjects affected / exposed	10 / 4101 (0.24%)	9 / 4110 (0.22%)	
occurrences causally related to treatment / all	1 / 10	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive crisis			
subjects affected / exposed	5 / 4101 (0.12%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 7	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive emergency			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive urgency			
subjects affected / exposed	1 / 4101 (0.02%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoperfusion			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hypotension			
subjects affected / exposed	37 / 4101 (0.90%)	49 / 4110 (1.19%)	
occurrences causally related to treatment / all	9 / 41	2 / 52	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hypovolaemic shock			
subjects affected / exposed	4 / 4101 (0.10%)	5 / 4110 (0.12%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Iliac artery stenosis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infarction			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jugular vein thrombosis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leriche syndrome			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant hypertension			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypertension			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension			
subjects affected / exposed	11 / 4101 (0.27%)	12 / 4110 (0.29%)	
occurrences causally related to treatment / all	2 / 13	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic venous thrombosis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			

subjects affected / exposed	18 / 4101 (0.44%)	17 / 4110 (0.41%)	
occurrences causally related to treatment / all	0 / 23	0 / 22	
deaths causally related to treatment / all	0 / 1	0 / 1	
Peripheral artery occlusion			
subjects affected / exposed	5 / 4101 (0.12%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery stenosis			
subjects affected / exposed	2 / 4101 (0.05%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery thrombosis			
subjects affected / exposed	2 / 4101 (0.05%)	6 / 4110 (0.15%)	
occurrences causally related to treatment / all	0 / 4	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 1	
Peripheral ischaemia			
subjects affected / exposed	14 / 4101 (0.34%)	9 / 4110 (0.22%)	
occurrences causally related to treatment / all	0 / 15	0 / 10	
deaths causally related to treatment / all	0 / 2	0 / 2	
Peripheral vascular disorder			
subjects affected / exposed	3 / 4101 (0.07%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 7	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral venous disease			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Phlebitis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post thrombotic syndrome			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shock			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Shock haemorrhagic			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis superficial			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicose vein ruptured			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vasculitis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis limb			
subjects affected / exposed	2 / 4101 (0.05%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Appendicectomy			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia prophylaxis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder catheter replacement			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac pacemaker replacement			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac resynchronisation therapy			
subjects affected / exposed	1 / 4101 (0.02%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary angioplasty			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery bypass			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary revascularisation			
subjects affected / exposed	2 / 4101 (0.05%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heart transplant			

subjects affected / exposed	2 / 4101 (0.05%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hernia diaphragmatic repair			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip arthroplasty			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hospitalisation			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Implantable defibrillator insertion			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implantable defibrillator removal			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia repair			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Knee arthroplasty			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Percutaneous coronary intervention			

subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Preoperative care			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toe amputation			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transurethral prostatectomy			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pregnancy, puerperium and perinatal conditions			
Ectopic pregnancy			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pregnancy			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	7 / 4101 (0.17%)	5 / 4110 (0.12%)	
occurrences causally related to treatment / all	0 / 9	0 / 6	
deaths causally related to treatment / all	0 / 2	0 / 1	
Cardiac death			
subjects affected / exposed	4 / 4101 (0.10%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 4	0 / 2	

Catheter site haemorrhage			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest discomfort			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	22 / 4101 (0.54%)	15 / 4110 (0.36%)	
occurrences causally related to treatment / all	2 / 23	1 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Complication associated with device			
subjects affected / exposed	0 / 4101 (0.00%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	49 / 4101 (1.19%)	65 / 4110 (1.58%)	
occurrences causally related to treatment / all	2 / 49	5 / 65	
deaths causally related to treatment / all	2 / 49	5 / 65	
Discomfort			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug withdrawal syndrome			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fatigue			
subjects affected / exposed	2 / 4101 (0.05%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gait disturbance			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gait inability			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	2 / 4101 (0.05%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 1	
Generalised oedema			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypothermia			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired healing			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated hernia			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inflammation			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza like illness			

subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Infusion site extravasation			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Localised oedema			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaise			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device site haematoma			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device site haemorrhage			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device site thrombosis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple organ dysfunction syndrome			
subjects affected / exposed	14 / 4101 (0.34%)	17 / 4110 (0.41%)	
occurrences causally related to treatment / all	1 / 14	0 / 17	
deaths causally related to treatment / all	1 / 9	0 / 10	
Nodule			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-cardiac chest pain			
subjects affected / exposed	27 / 4101 (0.66%)	33 / 4110 (0.80%)	
occurrences causally related to treatment / all	0 / 28	3 / 41	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema			
subjects affected / exposed	2 / 4101 (0.05%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema peripheral			
subjects affected / exposed	7 / 4101 (0.17%)	8 / 4110 (0.19%)	
occurrences causally related to treatment / all	0 / 7	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pacemaker generated arrhythmia			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Performance status decreased			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral swelling			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Physical deconditioning			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumatoxis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	6 / 4101 (0.15%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 7	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden cardiac death			
subjects affected / exposed	37 / 4101 (0.90%)	27 / 4110 (0.66%)	
occurrences causally related to treatment / all	2 / 37	0 / 27	
deaths causally related to treatment / all	2 / 37	0 / 27	
Sudden death			
subjects affected / exposed	58 / 4101 (1.41%)	52 / 4110 (1.27%)	
occurrences causally related to treatment / all	3 / 58	0 / 52	
deaths causally related to treatment / all	3 / 58	0 / 52	
Swelling face			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Systemic inflammatory response syndrome			
subjects affected / exposed	0 / 4101 (0.00%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulcer haemorrhage			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent occlusion			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent stenosis			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vessel puncture site haemorrhage			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Anaphylactic shock			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug hypersensitivity			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heart transplant rejection			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypersensitivity			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Social circumstances			
Physical assault			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Victim of homicide			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	5 / 4101 (0.12%)	5 / 4110 (0.12%)	
occurrences causally related to treatment / all	0 / 5	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epididymal cyst			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metrorrhagia			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatitis			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatomegaly			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scrotal oedema			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spermatocele			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			

Acute pulmonary oedema			
subjects affected / exposed	10 / 4101 (0.24%)	10 / 4110 (0.24%)	
occurrences causally related to treatment / all	0 / 10	0 / 10	
deaths causally related to treatment / all	0 / 3	0 / 1	
Acute respiratory distress syndrome			
subjects affected / exposed	2 / 4101 (0.05%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Acute respiratory failure			
subjects affected / exposed	18 / 4101 (0.44%)	20 / 4110 (0.49%)	
occurrences causally related to treatment / all	0 / 19	0 / 20	
deaths causally related to treatment / all	0 / 1	0 / 2	
Aspiration			
subjects affected / exposed	3 / 4101 (0.07%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 1	
Asthma			
subjects affected / exposed	6 / 4101 (0.15%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthma-chronic obstructive pulmonary disease overlap syndrome			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial disorder			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchiectasis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis chronic			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchopneumopathy			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchospasm			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	38 / 4101 (0.93%)	63 / 4110 (1.53%)	
occurrences causally related to treatment / all	0 / 54	0 / 81	
deaths causally related to treatment / all	0 / 3	0 / 3	
Chronic respiratory disease			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystic lung disease			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	31 / 4101 (0.76%)	28 / 4110 (0.68%)	
occurrences causally related to treatment / all	0 / 41	2 / 34	
deaths causally related to treatment / all	0 / 5	0 / 4	
Dyspnoea at rest			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Dyspnoea exertional			

subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			
subjects affected / exposed	5 / 4101 (0.12%)	5 / 4110 (0.12%)	
occurrences causally related to treatment / all	0 / 6	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			
subjects affected / exposed	4 / 4101 (0.10%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemothorax			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hydrothorax			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercapnia			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hypoxia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Idiopathic pulmonary fibrosis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Interstitial lung disease			

subjects affected / exposed	5 / 4101 (0.12%)	1 / 4110 (0.02%)
occurrences causally related to treatment / all	0 / 6	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0
Lung consolidation		
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Lung disorder		
subjects affected / exposed	2 / 4101 (0.05%)	3 / 4110 (0.07%)
occurrences causally related to treatment / all	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 0
Lung infiltration		
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Nasal polyps		
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Paranasal cyst		
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Pleural disorder		
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Pleural effusion		
subjects affected / exposed	14 / 4101 (0.34%)	11 / 4110 (0.27%)
occurrences causally related to treatment / all	0 / 16	1 / 11
deaths causally related to treatment / all	0 / 0	0 / 1
Pneumonia aspiration		

subjects affected / exposed	6 / 4101 (0.15%)	6 / 4110 (0.15%)	
occurrences causally related to treatment / all	0 / 6	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 2	
Pneumonitis			
subjects affected / exposed	2 / 4101 (0.05%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pneumothorax			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax spontaneous			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary arterial hypertension			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary artery thrombosis			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Pulmonary congestion			
subjects affected / exposed	3 / 4101 (0.07%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	13 / 4101 (0.32%)	20 / 4110 (0.49%)	
occurrences causally related to treatment / all	0 / 13	1 / 21	
deaths causally related to treatment / all	0 / 5	0 / 3	
Pulmonary haemorrhage			

subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary hypertension			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pulmonary mass			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary oedema			
subjects affected / exposed	12 / 4101 (0.29%)	14 / 4110 (0.34%)	
occurrences causally related to treatment / all	0 / 14	1 / 17	
deaths causally related to treatment / all	0 / 3	1 / 3	
Pulmonary vascular disorder			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory acidosis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory arrest			
subjects affected / exposed	2 / 4101 (0.05%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 2	
Respiratory disorder			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			

subjects affected / exposed	18 / 4101 (0.44%)	22 / 4110 (0.54%)	
occurrences causally related to treatment / all	0 / 22	0 / 22	
deaths causally related to treatment / all	0 / 2	0 / 8	
Sleep apnoea syndrome			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stridor			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillar hypertrophy			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheal stenosis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheomalacia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Alcohol abuse			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol withdrawal syndrome			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcoholism			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anxiety disorder			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anxiety			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Behaviour disorder			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bipolar disorder			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Communication disorder			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Completed suicide			
subjects affected / exposed	4 / 4101 (0.10%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 4	0 / 2	
Confusional state			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Conversion disorder			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delirium			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delusion			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	4 / 4101 (0.10%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Disorientation			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hallucination			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Major depression			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental disorder			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes			

subjects affected / exposed	4 / 4101 (0.10%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Panic attack			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Personality disorder			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychotic behaviour			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicidal ideation			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide attempt			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			
Device alarm issue			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device dislocation			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device electrical impedance issue			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device extrusion			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device inappropriate shock delivery			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device lead damage			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device lead issue			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device leakage			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device malfunction			
subjects affected / exposed	6 / 4101 (0.15%)	6 / 4110 (0.15%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device occlusion			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device physical property issue			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device power source issue			
subjects affected / exposed	1 / 4101 (0.02%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device signal detection issue			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device stimulation issue			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lead dislodgement			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oversensing			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Undersensing			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Acute hepatic failure			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Alcoholic liver disease			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autoimmune hepatitis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct obstruction			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct stone			
subjects affected / exposed	6 / 4101 (0.15%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary colic			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac cirrhosis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis			
subjects affected / exposed	1 / 4101 (0.02%)	6 / 4110 (0.15%)	
occurrences causally related to treatment / all	0 / 1	1 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis acute			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis			

subjects affected / exposed	9 / 4101 (0.22%)	11 / 4110 (0.27%)	
occurrences causally related to treatment / all	0 / 10	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			
subjects affected / exposed	18 / 4101 (0.44%)	11 / 4110 (0.27%)	
occurrences causally related to treatment / all	0 / 19	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis chronic			
subjects affected / exposed	0 / 4101 (0.00%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			
subjects affected / exposed	11 / 4101 (0.27%)	9 / 4110 (0.22%)	
occurrences causally related to treatment / all	1 / 12	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis obstructive			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholestasis			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cirrhosis alcoholic			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Congestive hepatopathy			
subjects affected / exposed	3 / 4101 (0.07%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	1 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug-induced liver injury			

subjects affected / exposed	2 / 4101 (0.05%)	5 / 4110 (0.12%)	
occurrences causally related to treatment / all	1 / 2	3 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cirrhosis			
subjects affected / exposed	2 / 4101 (0.05%)	5 / 4110 (0.12%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 2	
Hepatic failure			
subjects affected / exposed	4 / 4101 (0.10%)	5 / 4110 (0.12%)	
occurrences causally related to treatment / all	1 / 4	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic function abnormal			
subjects affected / exposed	3 / 4101 (0.07%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 3	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic ischaemia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic haematoma			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis acute			
subjects affected / exposed	0 / 4101 (0.00%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatocellular injury			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatorenal failure			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatorenal syndrome			
subjects affected / exposed	3 / 4101 (0.07%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 3	1 / 3	
deaths causally related to treatment / all	0 / 2	1 / 2	
Hepatotoxicity			
subjects affected / exposed	3 / 4101 (0.07%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	2 / 3	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Ischaemic hepatitis			
subjects affected / exposed	5 / 4101 (0.12%)	5 / 4110 (0.12%)	
occurrences causally related to treatment / all	0 / 5	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaundice			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaundice cholestatic			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Liver disorder			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver injury			

subjects affected / exposed	8 / 4101 (0.20%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	2 / 10	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Portal hypertension			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Portal vein thrombosis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Primary biliary cholangitis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venoocclusive liver disease			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	3 / 4101 (0.07%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anticoagulation drug level above therapeutic			
subjects affected / exposed	1 / 4101 (0.02%)	5 / 4110 (0.12%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anticoagulation drug level below therapeutic			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspartate aminotransferase			

increased			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood calcium decreased			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatinine increased			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood glucose decreased			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood magnesium decreased			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood potassium decreased			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac output decreased			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Catheterisation cardiac			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coagulation time prolonged			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ejection fraction decreased			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram QT prolonged			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HIV antibody positive			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram ST segment elevation			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoglobin decreased			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic enzyme abnormal			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic enzyme increased			
subjects affected / exposed	6 / 4101 (0.15%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	1 / 6	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza A virus test positive			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
International normalised ratio abnormal			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
International normalised ratio decreased			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
International normalised ratio increased			
subjects affected / exposed	2 / 4101 (0.05%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function test abnormal			
subjects affected / exposed	0 / 4101 (0.00%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 0	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function test increased			

subjects affected / exposed	2 / 4101 (0.05%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oxygen consumption increased			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SARS-CoV-2 test positive			
subjects affected / exposed	1 / 4101 (0.02%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcus test positive			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transaminases increased			
subjects affected / exposed	2 / 4101 (0.05%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	2 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transplant evaluation			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Troponin increased			
subjects affected / exposed	1 / 4101 (0.02%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Weight decreased			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Abdominal wound dehiscence			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Accidental exposure to product by child			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Accidental overdose			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol poisoning			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ankle fracture			
subjects affected / exposed	5 / 4101 (0.12%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial bypass thrombosis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriovenous fistula thrombosis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone contusion			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain contusion			

subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Burns third degree			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carbon monoxide poisoning			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac procedure complication			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac vein perforation			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract traumatic			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clavicle fracture			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Concussion			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contusion			

subjects affected / exposed	3 / 4101 (0.07%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniocerebral injury			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dialysis disequilibrium syndrome			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epidural haemorrhage			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eschar			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial bones fracture			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	7 / 4101 (0.17%)	10 / 4110 (0.24%)	
occurrences causally related to treatment / all	0 / 7	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral neck fracture			
subjects affected / exposed	8 / 4101 (0.20%)	8 / 4110 (0.19%)	
occurrences causally related to treatment / all	0 / 8	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			

subjects affected / exposed	14 / 4101 (0.34%)	11 / 4110 (0.27%)	
occurrences causally related to treatment / all	0 / 14	0 / 12	
deaths causally related to treatment / all	0 / 1	0 / 1	
Foot fracture			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foreign body in eye			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foreign body in gastrointestinal tract			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fracture			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Fracture displacement			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fractured coccyx			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrostomy tube site complication			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Graft thrombosis			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria traumatic			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hand fracture			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Head injury			
subjects affected / exposed	3 / 4101 (0.07%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 0	
Hip fracture			
subjects affected / exposed	5 / 4101 (0.12%)	7 / 4110 (0.17%)	
occurrences causally related to treatment / all	0 / 5	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 1	
Humerus fracture			
subjects affected / exposed	4 / 4101 (0.10%)	6 / 4110 (0.15%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyphaema			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incisional hernia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury			

subjects affected / exposed	2 / 4101 (0.05%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Injury corneal			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intentional overdose			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal anastomosis complication			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint dislocation			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint injury			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb crushing injury			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb injury			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb traumatic amputation			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower limb fracture			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscus injury			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture			
subjects affected / exposed	1 / 4101 (0.02%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple fractures			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple injuries			
subjects affected / exposed	0 / 4101 (0.00%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Osteophyte fracture			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Overdose			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Patella fracture			

subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic fracture			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periorbital haemorrhage			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumocephalus			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax traumatic			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural bile leak			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural complication			
subjects affected / exposed	0 / 4101 (0.00%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haematoma			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural fever			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haematuria			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haemorrhage			
subjects affected / exposed	1 / 4101 (0.02%)	5 / 4110 (0.12%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural hypotension			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postpericardiotomy syndrome			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural pneumothorax			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary contusion			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radius fracture			
subjects affected / exposed	2 / 4101 (0.05%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			

subjects affected / exposed	7 / 4101 (0.17%)	6 / 4110 (0.15%)	
occurrences causally related to treatment / all	0 / 7	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Scrotal haematoma			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin laceration			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skull fracture			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skull fractured base			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal compression fracture			
subjects affected / exposed	3 / 4101 (0.07%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal fracture			
subjects affected / exposed	0 / 4101 (0.00%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			

subjects affected / exposed	9 / 4101 (0.22%)	8 / 4110 (0.19%)	
occurrences causally related to treatment / all	0 / 9	0 / 8	
deaths causally related to treatment / all	0 / 2	0 / 2	
Subdural haemorrhage			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Synovial rupture			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon injury			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon rupture			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thermal burn			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thoracic vertebral fracture			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			

subjects affected / exposed	3 / 4101 (0.07%)	5 / 4110 (0.12%)	
occurrences causally related to treatment / all	0 / 3	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic haematoma			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic intracranial haemorrhage			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Upper limb fracture			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral injury			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular graft complication			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular graft occlusion			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular procedure complication			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular pseudoaneurysm			

subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vasoplegia syndrome			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vena cava injury			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Wound			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound complication			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wrist fracture			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Congenital megaureter			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocele			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertrophic cardiomyopathy			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Myocardial bridging			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-compaction cardiomyopathy			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	12 / 4101 (0.29%)	11 / 4110 (0.27%)	
occurrences causally related to treatment / all	3 / 12	2 / 12	
deaths causally related to treatment / all	0 / 1	1 / 2	
Acute left ventricular failure			
subjects affected / exposed	16 / 4101 (0.39%)	9 / 4110 (0.22%)	
occurrences causally related to treatment / all	0 / 20	0 / 14	
deaths causally related to treatment / all	0 / 1	0 / 0	
Acute myocardial infarction			
subjects affected / exposed	64 / 4101 (1.56%)	71 / 4110 (1.73%)	
occurrences causally related to treatment / all	7 / 70	3 / 73	
deaths causally related to treatment / all	0 / 16	0 / 16	
Acute right ventricular failure			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Angina pectoris			
subjects affected / exposed	40 / 4101 (0.98%)	41 / 4110 (1.00%)	
occurrences causally related to treatment / all	5 / 46	3 / 46	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina unstable			

subjects affected / exposed	49 / 4101 (1.19%)	63 / 4110 (1.53%)	
occurrences causally related to treatment / all	9 / 52	9 / 68	
deaths causally related to treatment / all	0 / 0	0 / 2	
Aortic valve disease			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve disease mixed			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve incompetence			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve stenosis			
subjects affected / exposed	3 / 4101 (0.07%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia			
subjects affected / exposed	6 / 4101 (0.15%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 1	
Arrhythmia supraventricular			
subjects affected / exposed	3 / 4101 (0.07%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerosis coronary artery			
subjects affected / exposed	7 / 4101 (0.17%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Atrial fibrillation			

subjects affected / exposed	113 / 4101 (2.76%)	94 / 4110 (2.29%)
occurrences causally related to treatment / all	5 / 127	3 / 112
deaths causally related to treatment / all	0 / 0	0 / 1
Atrial flutter		
subjects affected / exposed	25 / 4101 (0.61%)	23 / 4110 (0.56%)
occurrences causally related to treatment / all	1 / 29	3 / 24
deaths causally related to treatment / all	0 / 0	0 / 0
Atrial tachycardia		
subjects affected / exposed	9 / 4101 (0.22%)	9 / 4110 (0.22%)
occurrences causally related to treatment / all	1 / 9	1 / 9
deaths causally related to treatment / all	0 / 0	0 / 0
Atrial thrombosis		
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)
occurrences causally related to treatment / all	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Atrioventricular block		
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Atrioventricular block complete		
subjects affected / exposed	12 / 4101 (0.29%)	14 / 4110 (0.34%)
occurrences causally related to treatment / all	1 / 12	0 / 15
deaths causally related to treatment / all	0 / 1	0 / 3
Atrioventricular block second degree		
subjects affected / exposed	0 / 4101 (0.00%)	3 / 4110 (0.07%)
occurrences causally related to treatment / all	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
Bradyarrhythmia		
subjects affected / exposed	5 / 4101 (0.12%)	1 / 4110 (0.02%)
occurrences causally related to treatment / all	0 / 5	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0
Bradycardia		

subjects affected / exposed	3 / 4101 (0.07%)	8 / 4110 (0.19%)	
occurrences causally related to treatment / all	0 / 3	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bundle branch block left			
subjects affected / exposed	5 / 4101 (0.12%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac amyloidosis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac aneurysm			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	64 / 4101 (1.56%)	50 / 4110 (1.22%)	
occurrences causally related to treatment / all	3 / 66	2 / 52	
deaths causally related to treatment / all	1 / 42	2 / 46	
Cardiac asthma			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorder			
subjects affected / exposed	3 / 4101 (0.07%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Cardiac failure			
subjects affected / exposed	1045 / 4101 (25.48%)	988 / 4110 (24.04%)	
occurrences causally related to treatment / all	26 / 1879	30 / 1795	
deaths causally related to treatment / all	2 / 191	4 / 190	
Cardiac failure acute			

subjects affected / exposed	251 / 4101 (6.12%)	212 / 4110 (5.16%)	
occurrences causally related to treatment / all	10 / 362	10 / 308	
deaths causally related to treatment / all	2 / 28	0 / 41	
Cardiac failure chronic			
subjects affected / exposed	170 / 4101 (4.15%)	156 / 4110 (3.80%)	
occurrences causally related to treatment / all	5 / 236	2 / 199	
deaths causally related to treatment / all	1 / 40	0 / 33	
Cardiac failure congestive			
subjects affected / exposed	154 / 4101 (3.76%)	147 / 4110 (3.58%)	
occurrences causally related to treatment / all	5 / 234	7 / 208	
deaths causally related to treatment / all	2 / 19	1 / 24	
Cardiac flutter			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac tamponade			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac valve disease			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardio-respiratory arrest			
subjects affected / exposed	14 / 4101 (0.34%)	9 / 4110 (0.22%)	
occurrences causally related to treatment / all	0 / 14	1 / 9	
deaths causally related to treatment / all	0 / 13	1 / 7	
Cardiac ventricular thrombosis			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiogenic shock			

subjects affected / exposed	68 / 4101 (1.66%)	75 / 4110 (1.82%)	
occurrences causally related to treatment / all	1 / 70	5 / 77	
deaths causally related to treatment / all	0 / 30	3 / 42	
Cardiomyopathy			
subjects affected / exposed	8 / 4101 (0.20%)	12 / 4110 (0.29%)	
occurrences causally related to treatment / all	0 / 8	1 / 12	
deaths causally related to treatment / all	0 / 3	1 / 2	
Cardiopulmonary failure			
subjects affected / exposed	6 / 4101 (0.15%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 4	0 / 3	
Cardiorenal syndrome			
subjects affected / exposed	10 / 4101 (0.24%)	14 / 4110 (0.34%)	
occurrences causally related to treatment / all	0 / 10	0 / 14	
deaths causally related to treatment / all	0 / 3	0 / 3	
Cardiovascular insufficiency			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Chordae tendinae rupture			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic left ventricular failure			
subjects affected / exposed	8 / 4101 (0.20%)	6 / 4110 (0.15%)	
occurrences causally related to treatment / all	0 / 20	0 / 6	
deaths causally related to treatment / all	0 / 2	0 / 1	
Chronotropic incompetence			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Conduction disorder			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congestive cardiomyopathy			
subjects affected / exposed	24 / 4101 (0.59%)	14 / 4110 (0.34%)	
occurrences causally related to treatment / all	0 / 27	1 / 20	
deaths causally related to treatment / all	0 / 3	0 / 1	
Coronary artery disease			
subjects affected / exposed	24 / 4101 (0.59%)	26 / 4110 (0.63%)	
occurrences causally related to treatment / all	1 / 24	0 / 31	
deaths causally related to treatment / all	0 / 1	0 / 3	
Coronary artery insufficiency			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Coronary artery occlusion			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery stenosis			
subjects affected / exposed	10 / 4101 (0.24%)	6 / 4110 (0.15%)	
occurrences causally related to treatment / all	0 / 10	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extrasystoles			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive heart disease			
subjects affected / exposed	3 / 4101 (0.07%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Intracardiac thrombus			

subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic cardiomyopathy			
subjects affected / exposed	8 / 4101 (0.20%)	9 / 4110 (0.22%)	
occurrences causally related to treatment / all	0 / 16	0 / 9	
deaths causally related to treatment / all	0 / 1	0 / 2	
Left ventricular dysfunction			
subjects affected / exposed	3 / 4101 (0.07%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular failure			
subjects affected / exposed	4 / 4101 (0.10%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 2	
Low cardiac output syndrome			
subjects affected / exposed	3 / 4101 (0.07%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve incompetence			
subjects affected / exposed	8 / 4101 (0.20%)	9 / 4110 (0.22%)	
occurrences causally related to treatment / all	0 / 8	0 / 9	
deaths causally related to treatment / all	0 / 1	0 / 0	
Myocardial fibrosis			
subjects affected / exposed	3 / 4101 (0.07%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 1	
Myocardial infarction			
subjects affected / exposed	54 / 4101 (1.32%)	36 / 4110 (0.88%)	
occurrences causally related to treatment / all	7 / 56	3 / 36	
deaths causally related to treatment / all	3 / 20	1 / 16	
Myocardial ischaemia			

subjects affected / exposed	10 / 4101 (0.24%)	12 / 4110 (0.29%)	
occurrences causally related to treatment / all	0 / 13	0 / 12	
deaths causally related to treatment / all	0 / 2	0 / 4	
Myocarditis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Palpitations			
subjects affected / exposed	3 / 4101 (0.07%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	1 / 3	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paroxysmal arrhythmia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial haemorrhage			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pericarditis			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericarditis constrictive			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postinfarction angina			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Prinzmetal angina			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prosthetic cardiac valve thrombosis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulseless electrical activity			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	1 / 2	0 / 0	
Right ventricular dysfunction			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Right ventricular failure			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus arrest			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus bradycardia			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus node dysfunction			

subjects affected / exposed	2 / 4101 (0.05%)	5 / 4110 (0.12%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus tachycardia			
subjects affected / exposed	2 / 4101 (0.05%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular extrasystoles			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular tachyarrhythmia			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular tachycardia			
subjects affected / exposed	11 / 4101 (0.27%)	8 / 4110 (0.19%)	
occurrences causally related to treatment / all	0 / 11	1 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachyarrhythmia			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia			
subjects affected / exposed	5 / 4101 (0.12%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	1 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tricuspid valve incompetence			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Trifascicular block			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular arrhythmia			
subjects affected / exposed	18 / 4101 (0.44%)	24 / 4110 (0.58%)	
occurrences causally related to treatment / all	3 / 21	2 / 25	
deaths causally related to treatment / all	0 / 4	0 / 1	
Ventricular extrasystoles			
subjects affected / exposed	9 / 4101 (0.22%)	8 / 4110 (0.19%)	
occurrences causally related to treatment / all	0 / 10	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular fibrillation			
subjects affected / exposed	49 / 4101 (1.19%)	30 / 4110 (0.73%)	
occurrences causally related to treatment / all	5 / 52	3 / 31	
deaths causally related to treatment / all	0 / 9	0 / 5	
Ventricular flutter			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Ventricular tachyarrhythmia			
subjects affected / exposed	7 / 4101 (0.17%)	7 / 4110 (0.17%)	
occurrences causally related to treatment / all	0 / 7	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 1	
Ventricular tachycardia			
subjects affected / exposed	129 / 4101 (3.15%)	106 / 4110 (2.58%)	
occurrences causally related to treatment / all	12 / 149	12 / 138	
deaths causally related to treatment / all	0 / 4	0 / 6	
Nervous system disorders			
Alcohol induced persisting dementia			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Altered state of consciousness			

subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amnesia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Balance disorder			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain compression			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain hypoxia			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Brain injury			
subjects affected / exposed	2 / 4101 (0.05%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Brain oedema			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain stem stroke			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid arteriosclerosis			

subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery disease			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery occlusion			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery stenosis			
subjects affected / exposed	3 / 4101 (0.07%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carpal tunnel syndrome			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebellar haemorrhage			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral artery embolism			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cerebral circulatory failure			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haematoma			

subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cerebral haemorrhage			
subjects affected / exposed	7 / 4101 (0.17%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 1	
Cerebral hypoperfusion			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral infarction			
subjects affected / exposed	13 / 4101 (0.32%)	8 / 4110 (0.19%)	
occurrences causally related to treatment / all	0 / 13	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cerebral ischaemia			
subjects affected / exposed	4 / 4101 (0.10%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cerebrovascular accident			
subjects affected / exposed	29 / 4101 (0.71%)	25 / 4110 (0.61%)	
occurrences causally related to treatment / all	1 / 32	0 / 25	
deaths causally related to treatment / all	1 / 6	0 / 4	
Cerebrovascular disorder			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular insufficiency			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cognitive disorder			

subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coma			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Complex regional pain syndrome			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic neuropathy			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	8 / 4101 (0.20%)	6 / 4110 (0.15%)	
occurrences causally related to treatment / all	2 / 9	2 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness postural			
subjects affected / exposed	3 / 4101 (0.07%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	2 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysaesthesia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysarthria			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolic stroke			

subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Encephalopathy			
subjects affected / exposed	2 / 4101 (0.05%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epilepsy			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Generalised tonic-clonic seizure			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage intracranial			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic cerebral infarction			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic stroke			
subjects affected / exposed	7 / 4101 (0.17%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 7	0 / 3	
deaths causally related to treatment / all	0 / 6	0 / 1	
Haemorrhagic transformation stroke			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Headache			

subjects affected / exposed	4 / 4101 (0.10%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemianopia			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemiparesis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic encephalopathy			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocephalus			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemic unconsciousness			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoaesthesia			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemic unconsciousness			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic stroke			

subjects affected / exposed	38 / 4101 (0.93%)	36 / 4110 (0.88%)	
occurrences causally related to treatment / all	1 / 40	0 / 38	
deaths causally related to treatment / all	1 / 6	0 / 10	
Ischaemic cerebral infarction			
subjects affected / exposed	7 / 4101 (0.17%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Lacunar infarction			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lethargy			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss of consciousness			
subjects affected / exposed	2 / 4101 (0.05%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningism			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic encephalopathy			
subjects affected / exposed	5 / 4101 (0.12%)	5 / 4110 (0.12%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 1	0 / 0	
Mononeuritis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Monoplegia			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle contractions involuntary			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myoclonus			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuralgia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuromyopathy			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathy peripheral			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normal pressure hydrocephalus			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic intolerance			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parkinson's disease			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Partial seizures			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral sensorimotor neuropathy			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyneuropathy			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post-traumatic epilepsy			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			
subjects affected / exposed	5 / 4101 (0.12%)	8 / 4110 (0.19%)	
occurrences causally related to treatment / all	0 / 5	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychogenic seizure			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychomotor disadaptation syndrome			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychomotor hyperactivity			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radicular pain			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sciatica			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sedation			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure like phenomena			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Status epilepticus			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stroke in evolution			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Subarachnoid haemorrhage			

subjects affected / exposed	6 / 4101 (0.15%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	46 / 4101 (1.12%)	42 / 4110 (1.02%)	
occurrences causally related to treatment / all	1 / 51	0 / 43	
deaths causally related to treatment / all	0 / 0	0 / 1	
Thrombotic stroke			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Transient ischaemic attack			
subjects affected / exposed	24 / 4101 (0.59%)	17 / 4110 (0.41%)	
occurrences causally related to treatment / all	0 / 26	0 / 18	
deaths causally related to treatment / all	0 / 1	0 / 0	
Trigeminal neuralgia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebrobasilar insufficiency			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo CNS origin			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	28 / 4101 (0.68%)	34 / 4110 (0.83%)	
occurrences causally related to treatment / all	1 / 31	0 / 38	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia of chronic disease			

subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia vitamin B12 deficiency			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood loss anaemia			
subjects affected / exposed	2 / 4101 (0.05%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coagulopathy			
subjects affected / exposed	0 / 4101 (0.00%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cold type haemolytic anaemia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hypercoagulation			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypochromic anaemia			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune thrombocytopenia			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Iron deficiency anaemia			

subjects affected / exposed	3 / 4101 (0.07%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukopenia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Microcytic anaemia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normochromic anaemia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normochromic normocytic anaemia			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normocytic anaemia			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancytopenia			

subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic infarction			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spontaneous haematoma			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	5 / 4101 (0.12%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Deafness unilateral			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden hearing loss			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo			
subjects affected / exposed	3 / 4101 (0.07%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo positional			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vestibular disorder			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Amaurosis fugax			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerotic retinopathy			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract			
subjects affected / exposed	9 / 4101 (0.22%)	8 / 4110 (0.19%)	
occurrences causally related to treatment / all	0 / 13	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract diabetic			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic retinopathy			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diplopia			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye inflammation			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glaucoma			

subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iridodialysis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iris disorder			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular fibrosis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ocular hypertension			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pterygium			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal detachment			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scleromalacia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulcerative keratitis			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Visual impairment			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitreous haematoma			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitreous haemorrhage			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal adhesions			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal discomfort			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal distension			
subjects affected / exposed	3 / 4101 (0.07%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Abdominal hernia			
subjects affected / exposed	3 / 4101 (0.07%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal incarcerated hernia			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	13 / 4101 (0.32%)	6 / 4110 (0.15%)	
occurrences causally related to treatment / all	1 / 13	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			
subjects affected / exposed	5 / 4101 (0.12%)	6 / 4110 (0.15%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abnormal faeces			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute abdomen			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Anal fistula			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anorectal disorder			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	2 / 4101 (0.05%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic gastritis			

subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ischaemic			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis microscopic			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ulcerative			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	7 / 4101 (0.17%)	5 / 4110 (0.12%)	
occurrences causally related to treatment / all	0 / 7	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Crohn's disease			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dental caries			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic gastroparesis			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	12 / 4101 (0.29%)	6 / 4110 (0.15%)	
occurrences causally related to treatment / all	2 / 13	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dieulafoy's vascular malformation			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticular perforation			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum intestinal			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum intestinal haemorrhagic			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer haemorrhage			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenitis			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspepsia			

subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphagia			
subjects affected / exposed	1 / 4101 (0.02%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis			
subjects affected / exposed	3 / 4101 (0.07%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eiploic appendagitis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erosive oesophagitis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Food poisoning			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric disorder			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric haemorrhage			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric polyps			

subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer			
subjects affected / exposed	1 / 4101 (0.02%)	5 / 4110 (0.12%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer haemorrhage			
subjects affected / exposed	2 / 4101 (0.05%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer perforation			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	7 / 4101 (0.17%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 9	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis erosive			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis haemorrhagic			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal angiodysplasia			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorder			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	14 / 4101 (0.34%)	18 / 4110 (0.44%)	
occurrences causally related to treatment / all	0 / 14	1 / 19	
deaths causally related to treatment / all	0 / 2	0 / 2	
Gastrointestinal necrosis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal obstruction			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrooesophageal reflux disease			
subjects affected / exposed	7 / 4101 (0.17%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 7	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gingival bleeding			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematemesis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematochezia			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoperitoneum			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic erosive gastritis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoidal haemorrhage			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoids			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hernial eventration			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hiatus hernia			
subjects affected / exposed	1 / 4101 (0.02%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	5 / 4101 (0.12%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 2	0 / 2	
Ileus paralytic			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired gastric emptying			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated umbilical hernia			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	9 / 4101 (0.22%)	10 / 4110 (0.24%)	
occurrences causally related to treatment / all	0 / 9	0 / 10	
deaths causally related to treatment / all	0 / 1	0 / 0	
Inguinal hernia strangulated			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal angina			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal haemorrhage			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal infarction			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal ischaemia			
subjects affected / exposed	2 / 4101 (0.05%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 2	0 / 1	
Intestinal obstruction			

subjects affected / exposed	6 / 4101 (0.15%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal perforation			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Intra-abdominal haemorrhage			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intussusception			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Irritable bowel syndrome			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic enteritis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine perforation			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine polyp			
subjects affected / exposed	3 / 4101 (0.07%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower gastrointestinal haemorrhage			

subjects affected / exposed	2 / 4101 (0.05%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower gastrointestinal perforation			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mechanical ileus			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melaena			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesenteric arterial occlusion			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Mesenteric artery embolism			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Mesenteric vascular insufficiency			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Necrotising oesophagitis			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive pancreatitis			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal motility disorder			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal spasm			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal ulcer haemorrhage			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Oesophageal varices haemorrhage			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Oesophagitis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			

subjects affected / exposed	2 / 4101 (0.05%)	9 / 4110 (0.22%)	
occurrences causally related to treatment / all	0 / 2	1 / 10	
deaths causally related to treatment / all	0 / 0	0 / 3	
Pancreatitis haemorrhagic			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pancreatolithiasis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peptic ulcer haemorrhage			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal fissure			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	2 / 4101 (0.05%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal polyp			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal prolapse			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal haemorrhage			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	5 / 4101 (0.12%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subileus			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis mesenteric vessel			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Tooth disorder			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia			
subjects affected / exposed	0 / 4101 (0.00%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	9 / 4101 (0.22%)	10 / 4110 (0.24%)	
occurrences causally related to treatment / all	0 / 9	0 / 10	
deaths causally related to treatment / all	0 / 2	0 / 2	
Volvulus			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			

subjects affected / exposed	4 / 4101 (0.10%)	6 / 4110 (0.15%)	
occurrences causally related to treatment / all	0 / 4	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blister			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decubitus ulcer			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermal cyst			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis exfoliative			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis exfoliative generalised			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot			
subjects affected / exposed	6 / 4101 (0.15%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ulcer			

subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug eruption			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hair growth abnormal			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperhidrosis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peau d'orange			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pemphigoid			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pruritus			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	1 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoriasis			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Rash			

subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin erosion			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin lesion			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin necrosis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin ulcer			
subjects affected / exposed	7 / 4101 (0.17%)	6 / 4110 (0.15%)	
occurrences causally related to treatment / all	0 / 9	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stasis dermatitis			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic skin eruption			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	138 / 4101 (3.37%)	129 / 4110 (3.14%)	
occurrences causally related to treatment / all	6 / 161	6 / 152	
deaths causally related to treatment / all	0 / 6	0 / 8	
Anuria			

subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atonic urinary bladder			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Azotaemia			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neck obstruction			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus bladder			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus urinary			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic kidney disease			
subjects affected / exposed	36 / 4101 (0.88%)	36 / 4110 (0.88%)	
occurrences causally related to treatment / all	1 / 38	1 / 41	
deaths causally related to treatment / all	0 / 3	0 / 1	
Diabetic nephropathy			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
End stage renal disease			

subjects affected / exposed	4 / 4101 (0.10%)	7 / 4110 (0.17%)	
occurrences causally related to treatment / all	0 / 4	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 1	
Haematuria			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			
subjects affected / exposed	7 / 4101 (0.17%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage urinary tract			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydronephrosis			
subjects affected / exposed	2 / 4101 (0.05%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive nephropathy			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Micturition disorder			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	5 / 4101 (0.12%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 6	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephropathy			

subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Oliguria			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postrenal failure			
subjects affected / exposed	1 / 4101 (0.02%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal arteriosclerosis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal artery stenosis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal artery thrombosis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal colic			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cyst haemorrhage			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			

subjects affected / exposed	31 / 4101 (0.76%)	25 / 4110 (0.61%)	
occurrences causally related to treatment / all	1 / 31	2 / 26	
deaths causally related to treatment / all	0 / 0	0 / 3	
Renal haemorrhage			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal impairment			
subjects affected / exposed	29 / 4101 (0.71%)	25 / 4110 (0.61%)	
occurrences causally related to treatment / all	0 / 31	0 / 26	
deaths causally related to treatment / all	0 / 1	0 / 0	
Renal infarct			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureterolithiasis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral haemorrhage			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral stenosis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention			
subjects affected / exposed	2 / 4101 (0.05%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract obstruction			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Basedow's disease			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Goitre			
subjects affected / exposed	3 / 4101 (0.07%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia of malignancy			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperthyroidism			
subjects affected / exposed	2 / 4101 (0.05%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypothyroidism			
subjects affected / exposed	3 / 4101 (0.07%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 3	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroiditis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyrotoxic crisis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	4 / 4101 (0.10%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 7	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis			
subjects affected / exposed	3 / 4101 (0.07%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis reactive			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthropathy			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	6 / 4101 (0.15%)	7 / 4110 (0.17%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bursitis			
subjects affected / exposed	3 / 4101 (0.07%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Compartment syndrome			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Costochondritis			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dupuytren's contracture			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Elbow deformity			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial asymmetry			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fasciitis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Flank pain			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gouty arthritis			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemarthrosis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma muscle			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc compression			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion			
subjects affected / exposed	4 / 4101 (0.10%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint effusion			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb discomfort			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar spinal stenosis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mobility decreased			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle spasms			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscular weakness			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			

subjects affected / exposed	4 / 4101 (0.10%)	10 / 4110 (0.24%)	
occurrences causally related to treatment / all	0 / 4	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal disorder			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal pain			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myalgia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myofascial pain syndrome			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteitis			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	9 / 4101 (0.22%)	12 / 4110 (0.29%)	
occurrences causally related to treatment / all	0 / 11	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteochondritis			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteochondrosis			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteolysis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteonecrosis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoporotic fracture			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyarthritits			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polymyalgia rheumatica			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudarthrosis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhabdomyolysis			

subjects affected / exposed	4 / 4101 (0.10%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatoid arthritis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotator cuff syndrome			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal osteoarthritis			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal pain			
subjects affected / exposed	4 / 4101 (0.10%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylitis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Synovitis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tenosynovitis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral foraminal stenosis			

subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abdominal sepsis			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess jaw			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess limb			
subjects affected / exposed	4 / 4101 (0.10%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Acute endocarditis			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute hepatitis B			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal abscess			
subjects affected / exposed	3 / 4101 (0.07%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendiceal abscess			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			

subjects affected / exposed	3 / 4101 (0.07%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis perforated			
subjects affected / exposed	3 / 4101 (0.07%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerotic gangrene			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis bacterial			
subjects affected / exposed	2 / 4101 (0.05%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atypical pneumonia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	6 / 4101 (0.15%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial infection			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial sepsis			
subjects affected / exposed	3 / 4101 (0.07%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Bacterial tracheitis			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary sepsis			
subjects affected / exposed	0 / 4101 (0.00%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	24 / 4101 (0.59%)	25 / 4110 (0.61%)	
occurrences causally related to treatment / all	0 / 25	0 / 28	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis bacterial			
subjects affected / exposed	1 / 4101 (0.02%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis viral			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchopulmonary aspergillosis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Burn infection			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bursitis infective staphylococcal			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19			

subjects affected / exposed	3 / 4101 (0.07%)	8 / 4110 (0.19%)	
occurrences causally related to treatment / all	0 / 3	0 / 9	
deaths causally related to treatment / all	0 / 1	0 / 1	
COVID-19 pneumonia			
subjects affected / exposed	3 / 4101 (0.07%)	7 / 4110 (0.17%)	
occurrences causally related to treatment / all	0 / 3	0 / 7	
deaths causally related to treatment / all	0 / 1	0 / 4	
Catheter bacteraemia			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Catheter site infection			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	24 / 4101 (0.59%)	34 / 4110 (0.83%)	
occurrences causally related to treatment / all	0 / 27	0 / 36	
deaths causally related to treatment / all	0 / 1	0 / 1	
Chagas' cardiomyopathy			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cholecystitis infective			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic sinusitis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Citrobacter sepsis			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridial infection			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridial sepsis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			
subjects affected / exposed	2 / 4101 (0.05%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Complicated appendicitis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Conjunctivitis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dengue fever			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
subjects affected / exposed	5 / 4101 (0.12%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Device related sepsis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot infection			
subjects affected / exposed	2 / 4101 (0.05%)	6 / 4110 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic gangrene			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea infectious			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Diverticulitis			
subjects affected / exposed	2 / 4101 (0.05%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eczema infected			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolic pneumonia			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Empyema			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalitis			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis			
subjects affected / exposed	7 / 4101 (0.17%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 7	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 1	
Endocarditis bacterial			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Endocarditis enterococcal			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterobacter bacteraemia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterococcal bacteraemia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterococcal infection			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis bacterial			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis viral			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epididymitis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			
subjects affected / exposed	9 / 4101 (0.22%)	10 / 4110 (0.24%)	
occurrences causally related to treatment / all	0 / 9	0 / 11	
deaths causally related to treatment / all	0 / 2	0 / 0	
Escherichia infection			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia urinary tract infection			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fournier's gangrene			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fungal infection			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder abscess			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gangrene			
subjects affected / exposed	8 / 4101 (0.20%)	5 / 4110 (0.12%)	
occurrences causally related to treatment / all	0 / 8	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gas gangrene			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	11 / 4101 (0.27%)	15 / 4110 (0.36%)	
occurrences causally related to treatment / all	0 / 11	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis bacterial			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis norovirus			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal viral infection			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Graft infection			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Groin abscess			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis A			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis viral			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes dermatitis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes virus infection			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implant site infection			

subjects affected / exposed	1 / 4101 (0.02%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incision site abscess			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected seroma			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected skin ulcer			
subjects affected / exposed	5 / 4101 (0.12%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	6 / 4101 (0.15%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Infectious pleural effusion			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	3 / 4101 (0.07%)	4 / 4110 (0.10%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective myositis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective spondylitis			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Influenza			
subjects affected / exposed	15 / 4101 (0.37%)	19 / 4110 (0.46%)	
occurrences causally related to treatment / all	0 / 16	0 / 19	
deaths causally related to treatment / all	0 / 1	0 / 1	
Intervertebral discitis			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jejunal gangrene			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kidney infection			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Klebsiella bacteraemia			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Klebsiella sepsis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Labyrinthitis			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine infection			

subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngitis			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver abscess			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Localised infection			
subjects affected / exposed	6 / 4101 (0.15%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 7	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	6 / 4101 (0.15%)	7 / 4110 (0.17%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection viral			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung abscess			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenitis bacterial			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mediastinitis			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device site infection			
subjects affected / exposed	3 / 4101 (0.07%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis bacterial			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Metapneumovirus infection			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myiasis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Necrotising fasciitis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasopharyngitis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ophthalmic herpes zoster			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orchitis			

subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
subjects affected / exposed	12 / 4101 (0.29%)	8 / 4110 (0.19%)	
occurrences causally related to treatment / all	0 / 16	0 / 9	
deaths causally related to treatment / all	0 / 1	0 / 0	
Osteomyelitis acute			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis bacterial			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis chronic			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media bacterial			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parainfluenzae virus infection			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis			
subjects affected / exposed	5 / 4101 (0.12%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Peritonitis bacterial			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Peritonsillar abscess			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pilonidal cyst			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumococcal sepsis			
subjects affected / exposed	3 / 4101 (0.07%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pneumonia			
subjects affected / exposed	179 / 4101 (4.36%)	171 / 4110 (4.16%)	
occurrences causally related to treatment / all	0 / 207	0 / 191	
deaths causally related to treatment / all	0 / 20	0 / 13	
Pneumonia adenoviral			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia bacterial			
subjects affected / exposed	6 / 4101 (0.15%)	7 / 4110 (0.17%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia escherichia			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia haemophilus			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia influenzal			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia klebsiella			
subjects affected / exposed	2 / 4101 (0.05%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia moraxella			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia mycoplasmal			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia necrotising			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pneumonia pneumococcal			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia respiratory syncytial viral			

subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia staphylococcal			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia viral			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound infection			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic abscess			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudomembranous colitis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary sepsis			
subjects affected / exposed	4 / 4101 (0.10%)	6 / 4110 (0.15%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pulmonary tuberculosis			
subjects affected / exposed	4 / 4101 (0.10%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			

subjects affected / exposed	5 / 4101 (0.12%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis acute			
subjects affected / exposed	4 / 4101 (0.10%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus infection			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	24 / 4101 (0.59%)	15 / 4110 (0.36%)	
occurrences causally related to treatment / all	0 / 28	0 / 17	
deaths causally related to treatment / all	0 / 2	0 / 0	
Respiratory tract infection bacterial			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection fungal			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection viral			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scrotal abscess			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			

subjects affected / exposed	60 / 4101 (1.46%)	51 / 4110 (1.24%)
occurrences causally related to treatment / all	0 / 61	1 / 53
deaths causally related to treatment / all	0 / 13	1 / 16
Sepsis syndrome		
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0
Septic shock		
subjects affected / exposed	32 / 4101 (0.78%)	37 / 4110 (0.90%)
occurrences causally related to treatment / all	0 / 33	0 / 37
deaths causally related to treatment / all	0 / 10	0 / 18
Sinusitis		
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Sinusitis bacterial		
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)
occurrences causally related to treatment / all	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Skin graft infection		
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Soft tissue infection		
subjects affected / exposed	1 / 4101 (0.02%)	4 / 4110 (0.10%)
occurrences causally related to treatment / all	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0
Skin infection		
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Staphylococcal bacteraemia		

subjects affected / exposed	2 / 4101 (0.05%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal infection			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Staphylococcal sepsis			
subjects affected / exposed	5 / 4101 (0.12%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sterinitis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stitch abscess			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Streptococcal bacteraemia			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Streptococcal endocarditis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth abscess			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheitis			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth infection			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheobronchitis			
subjects affected / exposed	4 / 4101 (0.10%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tuberculoma of central nervous system			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tuberculosis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			
subjects affected / exposed	11 / 4101 (0.27%)	14 / 4110 (0.34%)	
occurrences causally related to treatment / all	0 / 12	0 / 14	
deaths causally related to treatment / all	0 / 2	0 / 0	
Urinary tract infection			
subjects affected / exposed	32 / 4101 (0.78%)	33 / 4110 (0.80%)	
occurrences causally related to treatment / all	0 / 33	1 / 39	
deaths causally related to treatment / all	0 / 2	0 / 0	
Urinary tract infection bacterial			
subjects affected / exposed	6 / 4101 (0.15%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection enterococcal			

subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection staphylococcal			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urogenital infection bacterial			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	15 / 4101 (0.37%)	7 / 4110 (0.17%)	
occurrences causally related to treatment / all	0 / 15	0 / 7	
deaths causally related to treatment / all	0 / 2	0 / 2	
Vascular device infection			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viraemia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			
subjects affected / exposed	3 / 4101 (0.07%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral upper respiratory tract infection			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound abscess			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection			
subjects affected / exposed	5 / 4101 (0.12%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection bacterial			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection staphylococcal			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound sepsis			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Abnormal loss of weight			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acidosis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cachexia			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decreased appetite			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	15 / 4101 (0.37%)	19 / 4110 (0.46%)	
occurrences causally related to treatment / all	0 / 17	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 1	
Diabetes mellitus			
subjects affected / exposed	8 / 4101 (0.20%)	15 / 4110 (0.36%)	
occurrences causally related to treatment / all	0 / 8	0 / 17	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus inadequate control			
subjects affected / exposed	5 / 4101 (0.12%)	6 / 4110 (0.15%)	
occurrences causally related to treatment / all	0 / 5	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketoacidosis			
subjects affected / exposed	5 / 4101 (0.12%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketosis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Diabetic metabolic decompensation			
subjects affected / exposed	8 / 4101 (0.20%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 8	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrolyte imbalance			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Failure to thrive			

subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fluid overload			
subjects affected / exposed	7 / 4101 (0.17%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	1 / 7	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fluid retention			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Folate deficiency			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gout			
subjects affected / exposed	7 / 4101 (0.17%)	14 / 4110 (0.34%)	
occurrences causally related to treatment / all	0 / 7	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	0 / 4101 (0.00%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	11 / 4101 (0.27%)	9 / 4110 (0.22%)	
occurrences causally related to treatment / all	0 / 11	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemic hyperosmolar nonketotic syndrome			
subjects affected / exposed	2 / 4101 (0.05%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			

subjects affected / exposed	21 / 4101 (0.51%)	20 / 4110 (0.49%)	
occurrences causally related to treatment / all	1 / 23	0 / 22	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hyperosmolar state			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperphosphataemia			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypervolaemia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoalbuminaemia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypocalcaemia			
subjects affected / exposed	1 / 4101 (0.02%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia			
subjects affected / exposed	13 / 4101 (0.32%)	7 / 4110 (0.17%)	
occurrences causally related to treatment / all	0 / 14	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	13 / 4101 (0.32%)	7 / 4110 (0.17%)	
occurrences causally related to treatment / all	0 / 14	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemic syndrome			

subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypomagnesaemia			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	19 / 4101 (0.46%)	14 / 4110 (0.34%)	
occurrences causally related to treatment / all	0 / 20	0 / 17	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypophagia			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemia			
subjects affected / exposed	1 / 4101 (0.02%)	3 / 4110 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lactic acidosis			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Latent autoimmune diabetes in adults			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malnutrition			
subjects affected / exposed	1 / 4101 (0.02%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic acidosis			

subjects affected / exposed	6 / 4101 (0.15%)	2 / 4110 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic alkalosis			
subjects affected / exposed	1 / 4101 (0.02%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obesity			
subjects affected / exposed	2 / 4101 (0.05%)	0 / 4110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 4101 (0.00%)	1 / 4110 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo	Omecamtiv Mecarbil	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1146 / 4101 (27.94%)	1129 / 4110 (27.47%)	
Vascular disorders			
Hypertension			
subjects affected / exposed	222 / 4101 (5.41%)	190 / 4110 (4.62%)	
occurrences (all)	276	229	
Hypotension			
subjects affected / exposed	242 / 4101 (5.90%)	276 / 4110 (6.72%)	
occurrences (all)	288	309	
Cardiac disorders			
Cardiac failure			
subjects affected / exposed	291 / 4101 (7.10%)	268 / 4110 (6.52%)	
occurrences (all)	363	340	
Nervous system disorders			

Dizziness subjects affected / exposed occurrences (all)	183 / 4101 (4.46%) 214	232 / 4110 (5.64%) 267	
Respiratory, thoracic and mediastinal disorders Dyspnoea subjects affected / exposed occurrences (all)	258 / 4101 (6.29%) 313	249 / 4110 (6.06%) 290	
Metabolism and nutrition disorders Hyperkalaemia subjects affected / exposed occurrences (all)	213 / 4101 (5.19%) 244	202 / 4110 (4.91%) 220	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
07 September 2017	<ul style="list-style-type: none">• Moved pharmacokinetic and associated assessments from week 24 to week 12;• Added electrocardiograms at screening and updated guidance language for electrocardiograms;• Clarified that there can be limited enrollment of subjects in atrial flutter at screening;• Clarified language around hospitalization in terms of inclusion criteria;• Updated inclusion criterion f_{q104} to provide guidance for qualifying left ventricle ejection fraction;• Updated the following exclusion criteria:<ul style="list-style-type: none">- #206 to indicate that noninvasive ventilation was permitted for specific indications;- #209 to include cardiac intervention and other cardiac valve repair;- #211 to include infiltrative cardiomyopathy;- #221 to indicate that subjects anticipated to receive cardiac support or heart transplantation were not eligible;• Clarified windows for randomization, day 1, and investigational product administration.
13 November 2018	<ul style="list-style-type: none">• Clarified in the Laboratory Assessments section that omecamtiv mecarbil plasma concentrations would be measured using an investigational assay, the QMS Omecamtiv Mecarbil Immunoassay developed by Thermo Fisher Scientific.• Update and aligned throughout the protocol language regarding disease-related events.• Removed language regarding self-evident corrections from the Study Monitoring and Data Collection section, because Amgen retired the use of self-evident corrections.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/33185990>